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The mechanism by which the hapten 2,4-dinitrophenyl (DNP) mediates cell 
death is unclear according to current literature. To determine how DNP mediates 
death in the B16F10 murine melanoma cell line in vitro, cells were modified with 
2,4-dinitro-1-fluorobenzene (DNFB). Following modification, cell lysates were 
collected and analyzed via Western blottings with known apoptotic or necrotic 
markers. Our results indicated that DNFB treated cells do not express the apoptotic 
marker Cleaved Caspase-3 and have no change in levels of the necrotic marker 
Cyclophilin A. We conclude that DNFB is not inducing apoptosis in B16F10 cells. 
Future research will further examine the possibility of necrotic cell death using a 
biomarker other then Cyclophilin A. 
 
Introduction 
My project will look into the mechanism of how DNP-modification causes 
death of B16F10 cells. Work by Cruz et al., 2003, indicates that DNP induces 
apoptosis with low concentrations of DNP, almost 1000-fold less than the 
concentration we use (7).  Our in situ DNP-mediated tumor regression model uses a 
26 mM DNFB injection at 40% of the tumor volume. To clarify the complex nature of 
our work, we will first explain the mechanism of apoptosis and necrosis as well as 
previous research that has led to our specific project. The mechanism of DNP-
mediated cell death is important to understand because it will give us insight into 
any anti-tumor immunity formed. 
 
Cell Death: 
 There are multiple ways that cells can die; apoptosis, necrosis, autophagy, 
and cornification (14).  Apoptosis is programmed cell death that has established 
phenotypic characteristics (5,8,14); cell shrinking, membrane blebbing, nuclear 
condensation, and nuclear fragmentation (1).  Apoptosis is required for the 
development of body parts, such as the fingers and toes, and for normal cell 
turnover (8).  Significant DNA damage, which might arise during mitosis or from 
certain cell abnormalities, such as nonfunctional mitochondria, will cause the cell to 
enter apoptosis.   
During division, cells have a normal cell cycle with four phases, each with its 
own checkpoint to make sure that the cell is healthy enough to divide.  These phases 
are: Gap 1 (G1), Gap 2 (G2), Synthesis (S), and Mitosis (M).  Within these phases are 
the G1 checkpoint, G2/M checkpoint, and the Metaphase/Anaphase checkpoint. 
During the G1 phase, a cell increases its size and prepares to replicate its DNA.  The 
G1 start checkpoint ensures that the cell is prepared to undergo DNA replication, if 
not then it will apoptose.  During S phase a cell replicates its DNA.  During the G2 
phase the cell undergoes growth (15).  The G2/M checkpoint occurs before mitosis 
and can initiate apoptosis if the cell’s DNA is badly damaged.  During the M phase a 
cell divides via mitosis and cytokinesis (1).  Mitosis consists of Prophase, Metaphase, 
Anaphase and Telophase.  During Prophase chromatin condenses into 
chromosomes.  During Metaphase the cell breaks down the nuclear membrane and 
the chromosomes align along the middle of the cell.  During Anaphase the 
chromosomes are pulled to the opposite sides of the cells by the centrioles.  During 
Telophase the nuclear membrane will reform and segregate to opposite sides of the 
cell (15).  The cell will lastly undergo Cytokinesis where the budding daughter cell 
membranes split completely and two new daughter cells are formed.  The cell will 
undergo the Metaphase/Anaphase checkpoint to ensure that the future daughter 
cells have equal numbers of chromosomes (1, 15).  
A key indicator of apoptotic cells is the appearance of “membrane flipping”, 
when the phospholipid membrane bilayer becomes inverted.  Healthy cell 
membranes have phosphatidyl serine, a phospholipid component that attaches to 
the cytoskeleton, on the cytosolic side of the membrane.  During apoptosis, the 
phosphatidyl serine will flip and face the extracellular space signaling macrophages 
that they are apoptotic. (14) 
Apoptosis is strongly regulated by the interaction of Cysteine proteases, 
Caspases.  Caspases cleave aspartic acid residues on peptides preceded by 
Isoleucine, Glutamic Acid, and Threonine.  Cleaved caspases initiate the caspase-
dependent apoptosis cascade (2).  Caspases are divided into two categories, Initiator 
Caspases 8, 9, and 12 and Effector Caspases 3, 6, and 7 (2,8,14).  Likewise, Apoptosis 
initiation is divided into two different pathways; the extrinsic and intrinsic, both of 
which converge to activate the downstream Effector caspase Cleaved Caspase-3. (2) 
The Initiator Caspases are cleaved into their active forms after they have 
received a specific death signal from either one of two pathways; the Extrinsic 
Pathway, which is activated via FasL-FasR stimuli to extracellular stimuli, or the 
Intrinsic Pathway, which is activated from either mitochondrial or endoplasmic 
reticulum signaling.  The Effector caspases are downstream of the Initiator caspases 
in the apoptosis signaling cascade.  In order for the Effector caspases to be activated, 
they require cleavage by the Initiator caspases.  In the extrinsic death receptor 
pathway, Fas Ligand (FasL) binds to Fas Receptor (FasR).  Both of these proteins are 
part of the Tumor Necrosis Factor (TNF) protein family.  The FasL-FasR pathway 
typically involves a Cytotoxic T-Cell’s FasL binding to a target cell’s FasR on its 
extracellular matrix.  This causes the cleavage of the inactive initiator caspase, Pro-
Caspase-8 into the active Cleaved Caspase-8. Cleaved Caspase-8 will cleave Pro-
Caspase-3 into the active Cleaved Caspase-3, which will cleave downstream 
apoptosis inducing proteins (2,5,8).  The Extrinsic Pathway takes place independent 
of the Intrinsic/Mitochondrial Pathway in which the death stimuli originate from 
within the cell. 
 Pro-Caspase-9 is converted to Cleaved Caspase-9 through the 
Intrinsic/Mitochondrial Pathway (2, 8).  Cytochrome c is an essential electron 
carrier in the electron transport chain in mitochondria.  If Cytochrome c escapes due 
to mitochondrial stress/damage, it will bind to and activate Apoptotic Protease 
Activating factor 1 (APAf1) (8), which forms a hexameric complex, “Apoptosome”, 
that (8) recruits and cleaves Pro-Caspase-9 into the active Cleaved Caspase-9. 
Cleaved Caspase-9 will cleave Pro-Caspase-3 into active Cleaved Caspase-3. (8) 
Caspase-12 modulates the level of Cleaved-Caspase-9 in the cell. When 
cellular stress increases, the Endoplasmic Reticulum (ER) of a cell will release Ca2+ 
ions into the nearby cytosol, activating m-calpain, which cleaves Pro-Caspase-12. 
Cleaved Caspase-12 cleaves Pro-Caspase-9 into Cleaved Caspase-9, which will cleave 
Pro-Caspase-3 as previously stated. (17) 
Initiator caspases cleave Pro-Caspase-3; Cleaved Caspase-3 will cleave 
Effector Caspases 6 and 7, which will participate in cleavage of proteins further 
downstream the apoptosis pathway (2).  Cleaved Caspase-3 also activates DFF (DNA 
Fragmentation Factor), causing the break down of the cell’s DNA. (9,19) 
Cleaved Caspase-3 can also inhibit the normal functions of Poly ADP Ribose 
Polymerase (PARP) and Alpha-Fodrin.  PARP is a repair enzyme that binds single 
stranded DNA segments and repairs nicks in them (8, 9,16).  Cleavage of PARP 
prevents the repair of internucleosomal DNA fragmentation brought about by the 
activation of DFF (9).  Alpha-Fodrin is a cytoskeletal protein, which maintains the 
integrity of the cellular membrane; its cleavage by Cleaved Caspase-3 and 7 is 
responsible for membrane blebbing in apoptotic cells. (8, 9, 10,13) 
Cleaved Caspase-6 cleaves Lamin A and in some cases Lamin B, a family of 
proteins which form the nuclear envelope and membrane of a cell (5).  The nuclear 
envelope is required to protect chromatin and modulate gene expression.  Cleaved 
Caspase-6’s destruction of Lamin A will cause the nuclear envelope to fall apart. (5).  
Unlike the aforementioned apoptotic pathway, the mechanism of necrotic 
death is much less understood.  Necrosis is unregulated traumatic cell death often 
caused by severe physical injury (3).  Unlike apoptosis, necrosis results in a release 
of a cell’s components into the extracellular environment.  Necrotic tissue can lead 
to inflammation near the site of cell death. (3,14) 
One well-known indicator of necrosis is High Mobility Group B1 (HMGB1).  
HMGB1 is located in the cell’s chromatin and normally functions as a transcription 
regulator.  During necrosis HMGB1 leaks out of the nucleus and into the 
extracellular environment, due to membrane permeabilization, where it can act as 
an inflammatory cytokine (3,6).  During apoptosis, HMGB1 tightly binds to 
nucleosomes and is not released (6).  Another necrotic biomarker is Cyclophilin A, a 
cytosolic isomerase released into the extracellular environment early in necrosis 
when the membrane has been permeabilized.  Cyclophilin A levels are high in 
unpermeabilized cells and low or absent in cells that have been permeabilized. (6)  
 Allergic contact dermatitis is an inflammatory skin disorder caused by 
contact with a small molecule, e.g. nickel (11).  Contact Hypersensitivity (CHS) is an 
animal model used to study allergic contact dermatitis (11).  CHS is induced through 
the application of a hapten to the epidermis.  Haptens are small compounds that can 
elicit an immune response once they are bound to a carrier protein, purified or 
cellular (7, 19).  The hapten used for our work is 2,4-dinitro-1-fluorobenzene 
(DNFB), which is deemed Dinitrophenyl (DNP) once it covalently binds to a carrier 
protein. (4, 7) 
 Haptens have been used to elicit anti-tumor immune responses.  Fujiwara et 
al., 1984 and 1985, observed regression of X5563 plasmacytoma tumors inoculated 
in C3H/HeN mice when treated with the hapten TNCB (Trinitrochlorobenzene).  The 
schedule of this treatment was as follows; mice were intra-pertoneally injected with 
1.5mg of Cyclophosphamide, then 2 days later TNCB was “painted” on the shaved 
abdomen of mice.  5 weeks later X5563 cells were injected into the flanks of mice.  
More than 50% of mice tumors regressed following intra-tumoral injection 0.5% 
TNCB in olive oil.  Similar results were found when using a Methylcholanthrene 
(MCA) inducible tumor system. (12, 24) 
Fujiwara’s work was used as a basis for clinical trials by Berd et al., 1993-
2004.  These trials examined tumor regression in stage III metastatic melanoma 
patients using the hapten DNFB (4).  Prior to surgical resection of tumors, patients 
received 300mg/m2 of Cyclophosphamide (4) and were sensitized to DNFB.  The 
resected tumor was then irradiated at 2500cGy, modified with DNFB, Intra-dermally 
injected into patients with 0.1mL Bacille Calmette Guerin (BCG).  Patients who 
received this treatment had a 5-year overall survival of 44% compared to 25% for 
traditional treatments, p<0.05 and this survival was correlated to several immune 
correlates (4).  Mokyr et al., 2002, took Berd et al.,’s vaccination method and applied 
it to a murine system.  They saw that overall survival was significantly improved 
from 25% in control Balb/c mice to 40% in treated Balb/c mice, (p<0.05) that were 
inoculated with the 410.4 mammary carcinoma and given the exact same treatment 
as the patients in the clinical trials.  Mice that had the highest overall survival 
received the DNP-modified vaccine along with a pre-treatment of 
Cyclophosphamide.  They also saw survival decrease when mice were given 
individual depleting antibodies for IFN-γ, CD-4 or CD-8 T-cells indicating an immune 
correlation to the vaccine. (21)  
Our lab is designing a mouse model for an in situ DNP-mediated melanoma 
vaccine; understanding the mechanism of DNP-mediated cell death may help us 
understand how DNP-modified melanoma cells are eliciting an anti-tumor immune 
response.  Cruz et al., 2003, showed that DNFB (2,4-dinitro-1-fluorobenzne) induces 
cellular apoptosis (7) in small concentrations.  FSDC dendritic cells were DNP-
modified with 5.2 uM, 13 uM, or 26 uM DNFB for 1 hour (7) and an 3-(4,5-
Dimethylthiazol-2-yl)-2-5-diphenyl terazolium bromide (MTT) assay was run to 
determine DNFB associated cell death.  Metabolism of the terazolium salt was 
severely inhibited in cells that received any concentration of DNFB.  Cells incubated 
in 13 uM DNFB for 3 and 6 hours displayed membrane blebbing (7) and Cleaved 
Caspase-3 activity, both indicating apoptosis.  Necrosis was noted to occur in cells 
that received higher concentrations of DNFB or incubated for extended periods of 
time via Flow Cytometry with the necrosis positive Propidium Iodide stain. (7,20) 
The haptens DNFB, DNCB (Dinitrochlorobenzene), and TNCB 
(Trinitrochlorobenzene) were found to induce apoptosis by Manome et al., 1999 
(23).  Human derived monocytes were cultured and treated with the haptens at 
varying concentrations, from 0.01 mM to 1 mM (19).  Flow Cytometry was 
performed on the cells with Annexin V, a dye that stains apoptotic cells by binding to 
the inverted phosphatidyl serines (19), and Propidium Iodide, a dye that stains 
necrotic cells by binding to nucleic acid base pairs (19).  As DNFB, DNCB, and TNCB 
concentrations increased, the ratio of necrotic to apoptotic cell death increased (19). 
However, this paper lacks crucial apoptotic protease Cleaved Caspase-3 evidence 
thus apoptosis needs further confirmation.  
Previous lab work examining the effect of DNP-modification on B16F10 cells 
suggested that these cells are not being killed via apoptosis.  An xCELLigence assay 
showed that healthily growing B16F10 cells would be dead within 3 hours of DNP-
modification with 0.52 mM DNFB.  Fluorescent microscopy showed the presence of 
Cleaved Caspase-3 in cells that were incubated with Staurosporine for 24 hours, a 
common apoptosis inducing agent (21), but not in cells incubated with 0.52 mM 
DNFB for 3 hours.  A western blot was run on these 0.52 mM DNFB treated cell 
lysates staining for Cleaved Caspase-3.  A positive cleaved caspase-3 signal only 
appeared for lysates that had incubated in 1 uM of Staurosporine for 20 hours, but 
not for any of the 0.52 mM DNFB treated time course B16F10 cells. This indicated 
that only the Staurosporine treated B16F10 cells were expressing cleaved caspase-
3, the enzyme required for apoptotic cell death. 
These previous studies indicate that DNFB causes cell death, although the 
exact cell death mechanism remains unclear at the high concentrations used in the 
lab.  We will investigate DNP-mediated cell death of B16F10 murine melanoma cells. 
To determine this, we will modify growing B16F10 cells with 0.52 mM of DNFB and 
perform time kinetics.  Cell lysates will be collected and used for Western Blotting. 
We will stain for the following; Pro-Caspase-3, Cleaved Caspase-3, Pro-Caspase-9, 
Cleaved Caspsae-9, Pro-Caspase-12, Cleaved PARP, Pro-Caspase-6, Cleaved Caspase-
6, and Cyclophilin A.  These experiments will provide us with insight into the 
mechanism of DNP-mediated cell death at the tumor site.  
Materials and Methods   
  
Cell Culturing: 
B16F10 cells, provided from frozen stocks courtesy of Dan Erkes, PhD 
scholar and Dr. Mizue Terai, PhD, were thawed at 37°C and added drop wise to 9 mL 
of Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% Fetal Bovine Serum (FBS) 
and 1% Penicillin/Streptomycin. Cellular suspensions were centrifuged at 1100 rpm 
for 5 minutes at room temperature twice, aspirating the supernatant each time and 
replacing it with 5 mL of new DMEM media. Cells were resuspended into 5 mL of 
DMEM and pipetted into 150x20 mm culture dishes (Sarstedt, #83.1803) with 14mL 
of DMEM. Cells were passaged once they had reached 80% confluency to avoid loss 
of cellular pigmentation and mutation. Cells were passaged by aspirating DMEM 
media from the plate and then gently washing with 1x PBS followed by aspiration of 
the PBS. 5 mL of 0.05% Trypsin: 0.53 mM EDTA (Gemini Bio-Products, 400-150) 
was added to the plate and then incubated at 37°C for 2 minutes. 10 mL of Hanks 
Balanced Salt Solution (HBSS) was used to wash the plate.  The cellular suspension 
was pipetted into a conical tube and centrifuged at 1100 rpm for 5 minutes at room 
temperature.  Supernatant was aspirated and replaced with 10mL of HBSS and 
centrifuged at 1100 rpm for 5 minutes at room temperature after 100uL of the 
suspension was placed in a hematocytometer and counted using Trypan Blue. 
Supernatant was aspirated and the cell pellet was resuspended in DMEM at 1 mL 
per million cells counted via the hematocytometer.  The cellular suspension was 
then pipetted into 150x20 mm culture dishes with 14 mL of DMEM, with a 
maximum of 2 million cells added per plate.   
 
Saponin, Staurosporine, and DNFB treatments of B16F10 cells: 
B16F10 cells were cultured as previously mentioned into 100x20 mm culture 
dishes (Sarstedt, #83.1802) and grown up until they had reached a confluency 
around 90%, which indicated that roughly 4 x 106 cells were present.  Cells were 
then given either one of the following three treatments: Saponin addition, 
Staurosporine addition, or DNFB modification.  For Saponin treatment, cells were 
scraped using a cell scraper and pipetted into a conical tube.  The tube was 
centrifuged at 1100rpm for 5 minutes at room temperature. Solution was aspirated 
off and the cell pellet was resuspended in 1 mL of Hanks Balanced Salt Solution 
(HBSS) with 1% Fetal Bovine Serum (FBS).  Premade serial dilutions of Saponin 
(Sigma-Aldrich, S-7900) in HBSS with 1% FBS were added to the conical tubes for 
final concentrations of: 0.02% Saponin, 0.004% Saponin, 0.0008% Saponin, and 
0.00016% Saponin. Solutions were incubated at room temperature for 5 minutes 
before being centrifuged, washed, and aspirated with 1x Phosphate Buffer Solution 
(PBS) twice and having their lysates collected. 1 uM Staurosporine treated samples 
were passaged into 100x20 mm culture dishes with 10 mL of Dulbecco’s Modified 
Eagle’s Medium (DMEM) until they reached 90% confluency. 100 uL of 
Staurosporine was then added to these plates and incubated at 37°C for one of the 
following time points: 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, and 24 hours. 
Lysates of these treated cells were then collected. DNFB-modified cells were 
cultured in 100x20mm culture dishes with 10 mL DMEM until they reached 90% 
confluency. To modify the adhered cells, 0.52 mM DNFB was added to healthily 
growing B16F10 cells.  Modified cells were then incubated at 37°C for the following 
time points: 0 hours, 0.25 hours, 0.5 hours, 0.75 hours, 1 hours, 1.5 hours, 2 hours, 3 
hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours.  Untreated B16F10 negative 
control cells were cultured in 100x20 mm culture dishes and were grown up until 
they reached 90% confluency upon which their lysates were collected. 
 
Lysate Collection: 
 Lysate collection was identical for each of the B16F10 treatments.  Treated 
cells were scraped using a cell scraper and the suspensions were pipetted into 
conical tubes.  Tubes were centrifuged at 1100 rpm for 5 minutes at 4°C. The 
supernatant was aspirated and the pellets were resuspended in 1xPBS at 4°C twice.  
After the second 1x PBS wash, spin, and aspiration cycle; the cell pellets were 
resuspended in 75 uL Pierce RIPA buffer with 1% Protease Inhibitor Cocktail and 
1% EDTA for 10 minutes.  The suspensions were pipetted into microcentrifuge 
tubes and centrifuged at 12,000 rpm for 10 minutes.  The supernatant (protein 
lysate) was pipetted into 3 different microcentrifuge tubes and flash frozen in liquid 




Stored lysates were placed in ice to passively thaw.  5 uL of lysate was added 
to 45 uL of 1x PBS into a microcentrifuge tube.  20 uL each was pipetted into 2 new 
microcentrifuge tubes with 1 mL of QuickStart Bradford Reagent Dye and incubated 
at room temperature for 10 minutes. The same procedure was followed for the 
Pierce RIPA control buffer with Bradford Reagent Dye. A PBS control was set up by 
adding 20 uL of 1x PBS to 1 mL of QuickStart Bradford Reagent Dye in a 
microcentrifuge tube and incubating for 10min. The liquid in the tubes was then 
pipetted into cuvettes and the absorbances were recorded. To calculate the 
appropriate volume of solution to add to a Western blot well for 40 ug of protein, a 
standard curve was generated using Bovine Serum Albumin (BSA). The absorbances 
of the known concentrations of BSA samples were recorded and their averages 
plotted graphically to generate an equation for a best-fit line protein concentration 
vs. absorbance. Once the absorbances of the lysates were averaged, this value was 
placed into the BSA-generated equation to solve for the “x” volume of lysate to add 
to equal 40 ug of protein. The value was then multiplied by 10 to account for the 
dilution factor and multiplied by 1000 to convert the BSA values from mg to ug. The 
value from the RIPA absorbance was subtracted from the lysate values and this new 
value was divided by 1000 to convert from mL to uL.  The new value was then 
divided into 40 to yield the uL necessary to equal 40 ug of protein, which we would 
add to our SDS-Page gel.   
 
WESTERN blots:    
The Apoptosis antibody sampler kit (Mouse Preferred) for WESTERNs by 
Cell Signaling (9930S) contained the following apoptosis markers: Caspase-3, 
Cleaved Caspase-3, Caspase-6, Cleaved Caspase-6, Cleaved PARP, Caspase-12, 
Caspase-9, and Cleaved Caspase-9.  Necrosis marker included: Cyclophilin A 
antibody (Cell Signaling, 32175).  Secondary antibodies used were Anti-rabbit IgG 
HRP-linked antibody. 10% and 16% Novex Tris-Glycine Gels by life technologies 
were used (EC64986BOX).  Positive apoptosis control and negative apoptosis 
controls used were Cytochrome c Treated Jurkat Cells and Untreated Jurkat Cells, 
respectively (Cell Signaling, 9663S).  The western blotting apparatus was set up 
with either a 15-well or 10-well 16% Novex Tris/Glycine gel, depending upon the 
number of protein lysates being run at the time.  Lysates were added in a 1:1 ratio 
with SDS Loading Buffer into a microcentrifuge tube according to the Bradford 
Assay results.  Tubes were placed in a 98°C heating block for 5 minutes.  The 
previously established volume for 40 ug of protein was then pipetted into the 
appropriate well along with a Sharp Protein Standard Ladder.  The gel was run at 
125 V until the blue dye was at the bottom of the gel.  Gels were then removed from 
apparatus and placed on Novex membranes in transfer cassettes in 4°C Western 
Blotting Running Transfer Buffer.  Cassettes were then placed in the gel transfer 
apparatus with transfer buffer an ice pack and in an ice bucket.  The transfer of the 
gel to the membrane was run at 100 V for 90 minutes.  Once the gel was transferred 
onto the membrane, the membrane was washed in 1xTBS-T. 10 mL of 5%MILK 
1xTBS-T was added to the membrane and placed on a shaker for 1 hour at room 
temperature for membrane blocking.  The membrane was incubated with 5mL of 
the appropriate 1° antibody (1:1000 dilution) in 5% MILK 1xTBS-T on a shaker 
overnight at 4°C. The membrane was washed three times with 1xTBS-T and then 
incubated with 5 mL of Rabbit IgG,HRP-linked (1:2500) 2° antibody in 5% MILK 1x-
TBS-T on a shaker for 1 hour at room temperature.  The membrane was then 
washed 3x with 1xTBS-T before it received 2.5 mL of Reagent 1 and 2.5mL of 
Reagent 2 of Amersham ECL and shook at room temperature for 2 minutes.  The 
membrane was then placed in a plastic casing and exposed to Hyblot 
Autoradiography film for the appropriate time points.  Film was then developed in 
the Dark Room at the Bluemle Life Sciences Building Room 936. 
 
Results 
Morphology of DNP-modified B16F10 cells 
To assess the mechanism by which DNP-mediates cell death in vitro, images 
of the cells were taken after they were treated with either 0.52 mM DNFB or 1 uM 
Staurosporine and incubated for various time points.  Apoptotic cells display the 
prototypical characteristics of; membrane blebbing, cell shrinking, and nuclear 
condensation.  However, necrotic cells typically display a destroyed or 
permeabilized membrane only.  In Figure 1A, Staurosporine treated B16F10 cells 
display apoptotic membrane blebbing and cell shrinking.  DNFB treated cells 
became rounded about 4 hours after they had been modified and nuclei were 
normally shaped (Figure 1B).  This morphology is not indicative of either apoptosis 
or necrosis.  However, it is difficult to accurately make an assessment without more 
in-depth microscopy.  These samples were collected for Western blottings. 
 
 
Figure 1. Morphology of DNP-modified B16F10 Cells.  B16F10 cells were either 
modified with 0.52 DNFB and incubated for various time points or treated 1 uM 
Staurosporine for 4 hours and Images were taken before the lysates of these cells 
were collected for western blotting A.) Untreated B16F10 cells healthily growing in 
culture and B16F10 cells 1 uM Staurosporine for 4 hours at 37°C.  B.) DNP-modified 
B16F10 cells incubated for various time points at 37°C.  
 
Staurosporine Apoptosis Control 
 To identify the optimal Cleaved Caspase-3 expression level for our positive 
apoptosis control, time kinetics were performed using 1 uM Staurosporine 
treatments on B16F10 cells (Figure 2).  1 uM Staurosporine was found to induce the 
strongest Cleaved Caspase-3 signal 4 hours after administration.  Signal strength 
dissipated in subsequent samples; Cleaved Caspase-3 signal was completely absent 
24 hours after administration.  Pro-Caspase-3 signal strength was equivalent for all 
samples except for the positive apoptosis Cell Signaling Cytochrome c treated Jurkat 
Cells company control.  To ensure that protein levels were of comparable size, an 
Anti-Actin stain was run and all samples had similar levels of protein.  These results 
identified the 4 hours Staurosporine treatment time point to yield the highest 
Cleaved Caspase-3 signal, which we will use as an apoptosis positive control in all 
future DNP-mediated cell death experiments. 
 
Figure 2. 1 uM Staurosporine Treated B16F10 cells Time Course. B16F10 cells 
were treated with 1 uM Staurosporine for various time points before the lysates 
were collected and western blotted.  Pro-Caspase-3 is present in all but the 
Cytochrome C treated Jurkat cell sample and is unaffected by the level of Cleaved 
Caspase-3 expression.  However, Cleaved Caspase-3 is strongest in the Cytochrome c 
treated Jurkat control and the B16F10 cells treated with Staurosporine for 4 hours.  
This Cleaved Caspase-3 signal dissipates with time and is completely absent after 24 
hours. 
 
Saponin Necrosis Control 
To identify a positive necrosis control, the detergent Saponin was serially 
diluted in HBSS with 1% FBS and administered to B16F10 based on the 
permeabilization procedure using digitonin laid out by Christofferson and Yuan, 
2010 (6). Using Trypan Blue staining to determine cell death by permeabilization, 
cell permeabilization was found to decrease as Saponin concentrations decreased 
(Figure 3).  The largest drop in permeabilization occurred between the 0.004% 
Saponin concentration and the 0.0008% Saponin.  Cyclophilin A signals were 
equally strong amongst all the treated samples and the untreated B16F10 sample; 
this showed that Saponin treatment did not cause the release of Cyclophilin A from 
B16F10 cells.  
 
 
Figure 3. Saponin Treated B16F10 cells at Various Concentrations.  B16F10 cells 
were treated with various concentrations of Saponin and incubated at room 
temperature for 5 minutes.  Prior to lysate collection of these samples percent 
permeabilization was performed using Trypan Blue.  As Saponin concentration 
decreases, the percent permeabilization of B16F10s also decreases.  Cyclophilin A 
levels in the lysates remained constant regardless of the Saponin concentration 
added. 
 
DNFB Time Kinetics with Dan Erkes’ Lysates 
 Lysates collected by Dan Erkes, PhD Scholar were western blotted for 
Cleaved Caspase-3 and Cyclophilin A.  Cleaved Caspase-3 expression was only 
present in the Staurosporine treated B16F10 cells. Cyclophilin A was present in all 
the samples, except lane 4, at similar intensities unlike our lab’s previous results. 
The absence of Cyclophilin A in lane 4, 0.25 hours modification with 0.52 mM DNFB, 
could have resulted from an inadequate level of protein being added to the well, 
which was confirmed via an Anti-Actin stain. 
  
Figure 4. DNP-modification of B16F10 Time Kinetics with Dan Erkes’ Lysates. 
To repeat the previous experiment run by Dan Erkes, PhD scholar, we reran a 
Western blot on his previously collected lysates.  Cleaved Caspase-3 was found to be 
expressed only in the 1 uM Staurosporine positive apoptosis control that had 
incubated at 37°C for 20 hours.  Cyclophilin A was present at similar concentrations 
in all samples except for the 0.25 hours DNFB lysate. 
 
Time Kinetics of DNFB treated B16F10 cells 
 A time kinetics western blot of DNFB treated B16F10 cells was repeated 
following the previously outlined protocol.  The lysates collected from these 
modifications were analyzed protein content via Bradford Assay and western 
blotted.  Cleaved Caspase-3 expression was present only for the B16F10 cells 
treated with 1 uM Staurosporine for 4 hours and no Cleaved Caspase-3 expression 
was present for any of the DNFB treated samples.  Levels of Cyclophilin A were 
similar for all samples regardless of whether they were treated with DNFB or 
Staurosporine (Figure 5).  The Actin stain indicated that there was similar protein 






























Figure 5. Time Kinetics of DNFB Lysates for Cleaved Caspase-3 and Cyclophilin 
A. A time kinetics Western blot was performed following the same protocol as 
before.  The resulting blot produced a clear Cleaved Caspase-3 signal for only the 
B16F10 lysates incubated at 37°C for 4 hours with 1 uM Staurosporine.  Cyclophilin 
A levels were present in all the samples and levels did not fluctuate depending upon 
the treatment or incubation time.  The Anti-Actin blot showed that protein was 
present in each well.  
Conclusions 
 My goal was to modify B16F10 cells with 0.52 mM DNFB.  Cell lysates would 
then be collected and ran in a western blot to analyze the levels of apoptotic and 
necrotic protein markers.  Our lab believed that DNP-modified B16F10 cells would 
not express Cleaved Caspase-3, but would express Cyclophilin A indicating necrotic 
cell death.  The absence of Cleaved Caspase-3 expression (figures 4 & 5) indicates 
that B16F10 cells are not dying of apoptosis when treated with DNFB.  Cleaved 
Caspase-3 is required for the caspase-dependent process of apoptosis and it is 
unlikely to occur without this crucial enzyme (8).  This information confirms our 
hypothesis that B16F10 cells when treated with DNFB do not die from apoptosis. 
However, this does not confirm the mechanism of DNP-mediated cell death 
occurring in these cells. 
Cyclophilin A is a cytosolic isomerase that is lost to the extracellular 
environment when a cell becomes necrotic (6).  A necrotic cell thus would be absent 
or highly depleted of it when compared to an apoptotic or healthy cell as noted by 
Christofferson and Yuan, 2010 (6).  We did not find Cyclophilin A decrease or 
absence with extended DNFB incubations in B16F10 cells during any of our three 
trials (figures 4 & 5).  Levels of Cyclophilin A did not change in DNFB treated groups 
compared to our controls.  From this data we conclude that Cyclophilin A is not 
released from B16F10 cells when they are treated with 0.52 mM DNFB and 
therefore necrosis cannot be confirmed via the presence of Cyclophilin A.  This 
result differs from the literature possibly because we are using a different cell line, 
Christofferson and Yuan, 2010,  used the L929 cell line and we use the B16F10 cell 
line, which may not release Cyclophilin A upon permeabilization (6).  Also, 
Christofferson and Yuan, 2010, used Digitonin as their positive necrosis control, 
while we used Saponin which was not a good positive control for necrosis (6).   In 
the future, we plan on using Christofferson and Yuan’s 2010 protocol, using 
Digitonin, to produce a positive control for Cyclophilin A in B16F10 cells (6). O nce 
we have established this control, we will then rerun our DNP modifications. In 
addition, we will examine the release of HMGB1 during DNP modification as a 
marker of necrosis. (3, 6).  Future research by our lab will include further 
investigation into the mechanism of DNP-mediated cell death.  The next logical step 
would be to test for the absence or presence of HMGB1 in DNFB-treated B16F10 
cells. (3,14).  
Our current results differ from previously observed ones in the established 
literature.  Literature on DNP-modification of cells shows death via apoptosis when 
concentrations of DNFB range from 5.2 uM, 13 uM, and 26uM which are all much 
lower than our own 0.52 mM concentration.  Both Cruz et al., and Manome, et al., 
used DNFB concentrations nearly 1000-fold less than the concentrations our lab 
uses (7, 23).  Also, both Cruz and Manome used different cell lines then we did, FSDC 
dendritic cells and peripheral blood mononuclear cells respectively (7, 23).  Results 
seen in these cell lines may not translate to B16F10 cells treated with a much higher 
DNFB concentration than in previous studies (0.52 mM).  These differences may be 
why our results differed from the results of Cruz et al., 2003 and Manome et al., 
1999. 
The mechanism for DNP-mediated cell death is still unclear.  We have 
observed the absence of Cleaved Caspase-3 in DNFB treated B16F10 cells which 
suggests that apoptosis is not being induced in these cells as we originally 
hypothesized.  DNP-mediated necrosis of B16F10 cells can neither be confirmed nor 
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